Baltimore-based AgeneBio announced a pair of grants from the National Institutes of Health that will assist with clinical trials of a treatment to combat the progression of Alzheimer’s disease.
The awards from the NIH’s National Institute of Aging and the National Institute of Neurological Disorders and Stroke are expected to provide $16 million in funding, the company states.
The company’s work is based on the research of Dr. Michela Gallagher, who heads the Neurogenetics and Behavior Center at Johns Hopkins University and is currently serving as CEO of the company while on leave from the university. The research shows that overactivity in the hippocampus contributes to cognitive impairment. AgeneBio is developing treatments to slow Mild Cognitive Impairment due to Alzheimer’s disease. The condition causes a noticeable decline in cognitive abilities including memory, according to the Alzheimer’s Association.
According to the Mt. Washington–based company, the grants fund a Phase III clinical trial of a therapeutic to treat the condition. Dubbed the “Hope4MCI” trial, it will include a sub-study that includes imaging tools developed by Cerveau Technologies and Johns Hopkins Center for Imaging Science to track how the disease effects the brain, and the potential to slow it down.
Phase 3 trials typically precede an application to the FDA for approval to market a product.
“Previous support by NIA has already enabled us to complete study start up activities for the HOPE4MCI trial,” Sharon Rosenzweig-Lipson, AgeneBio’s Vice President of Research and Development, said in a statement. “The new grant will allow us to rapidly begin enrollment in the trial putting us one step closer to understanding the impact of hippocampal overactivity and tau pathology in this disease and to being able to treat MCI due to AD.”
Dr. Gallagher was also recently awarded the 2018 Melvin R. Goodes Prize for Excellence in Alzheimer’s Drug Discovery by the Alzheimer’s Drug Discovery Foundation, which came with a $150,000 award that is being used toward the Phase 3 trial, according to a news release.
Another grant is supporting a separate therapeutic that is designed to normalize brain functions in the early stages of Alzheimer’s.
Before you go...
Please consider supporting Technical.ly to keep our independent journalism strong. Unlike most business-focused media outlets, we don’t have a paywall. Instead, we count on your personal and organizational support.
3 ways to support our work:- Contribute to the Journalism Fund. Charitable giving ensures our information remains free and accessible for residents to discover workforce programs and entrepreneurship pathways. This includes philanthropic grants and individual tax-deductible donations from readers like you.
- Use our Preferred Partners. Our directory of vetted providers offers high-quality recommendations for services our readers need, and each referral supports our journalism.
- Use our services. If you need entrepreneurs and tech leaders to buy your services, are seeking technologists to hire or want more professionals to know about your ecosystem, Technical.ly has the biggest and most engaged audience in the mid-Atlantic. We help companies tell their stories and answer big questions to meet and serve our community.
Join our growing Slack community
Join 5,000 tech professionals and entrepreneurs in our community Slack today!
